A Prolonged Nightly Fasting for Men on ADT for PCa

Korábbi kezelés

• An individual who meets any of the following criteria will be excluded from participation in this study:
  • Inability to tolerate a normal diet (may include an active malabsorption syndrome at time of consent (i.e. Crohn's disease, major bowel resection leading to permanent malabsorption)
  • Patients on concurrent chemotherapy will be excluded.
  • ECOG score > 2
  • Medications such as finasteride/dutasteride/saw palmetto are not allowed.
  • Insulin injection or glyburide medication

• Individuals must meet all of the following inclusion criteria in order to be eligible to participate in the study:
  • Must be 18 years of age or older
  • Provide signed and dated informed consent form
  • Had a histological diagnosis of PCa (Stage IIA-IVB)
  • Are beginning or receiving ADT (including medical castration with LHRH-agonist-antagonist androgen receptor modulators) for PCa with an anticipated duration of ≥ 3 months. The ADT is defined as: (a) Gonadotropin Releasing Hormone (GNRH) agonist (including leuprolide [Lupron/Eligard], goserelin [Zoladex], triptorelin [Trelstar], histrelin [Vantas], and abiraterone [Zytiga]) alone; (b) GNRH agonist with oral androgen receptor blockade (including bicalutamide [Casodex], flutamide [Eulexin], and enzalutamide [Xtandi]), and (c) GNRH agonist, oral androgen receptor blockade, and 5-alpha reductase inhibitors. Patients on androgen receptor modulators and second-generation androgen receptor antagonists will qualify.
  • Intermittent ADT will be allowed as long as the overall duration is more than 3 months.
  • BMI ≥25 kg/m2
  • Radiation therapy will be allowed concurrently.
  • Willing and able to comply with the protocol for the duration of the study
  • Able to speak, read and write English
  • Has a mobile phone with TXT capability.